|Podcasts|May 25, 2023

Emerging Potential: Changing Lives One Story, One Therapeutic at a Time

Author(s)Meg Rivers

The 2023 Emerging Pharma Leaders share with the Pharmaceutical Executive editors what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. (This is the audio-only Pharm Exec Podcast episode!)

Each year, Pharmaceutical Executive recognizes up-and-coming leaders who are vital to the future of the pharmaceutical and biotech industry in the Emerging Pharma Leaders (EPL) Awards. Nominations are judged by three members of the Editorial Advisory Board as well as a former EPL representative. This year, five winners were selected, all of whom had incredible journeys to share with the editorial team.

The Pharm Exec team would like to congratulate the 2023 Emerging Pharma Leaders:

  1. Natasha A. Hernday, chief business officer, Seagen
  2. Simon Holland, vice president, women's health commercial lead, Organon
  3. Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio
  4. Frank Watanabe, president and CEO, Arcutis Biotherapeutics
  5. Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics

In this episode of the Pharm Exec Podcast, Meg Rivers, managing editor, and the editorial team speak with the EPL winners, asking each about:

  • Their current role and responsibilities
  • What makes a good leader
  • What has made them the proudest in their career 
  • Lessons they wish they had known when starting out
  • What’s next for them in their career


Sponsor

APEX Awards


Watch the video version of this podcast


Read about the 2023 Emerging Pharma Leaders


About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.